Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

781

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Generalized Anxiety Disorder
Interventions
DRUG

Placebo

Placebo-matching capsules

DRUG

Vortioxetine

Encapsulated vortioxetine immediate release tablets

DRUG

Duloxetine

Overencapsulated duloxetine capsules

Trial Locations (66)

Unknown

Anaheim

Beverly Hills

Fresno

Los Angeles

Oceanside

San Diego

Sherman Oaks

Widomar

Denver

Farmington

Norwalk

Coral Gables

Jacksonville

Maitland

Miami

Orlando

Tampa

West Palm Beach

Winter Park

Atlanta

Roswell

Smyrna

Honolulu

Oakbrook Ter

Terre Haute

Owensboro

Shreveport

Rockville

Chesterfield

St Louis

Nashua

Clementon

Princeton

Albuquerque

Brooklyn

Cedarhurst

New York

Rochester

Staten Island

Charlotte

Raleigh

Beachwood

Cleveland

Dayton

Toledo

Eugene

Portland

Salem

Allentown

Media

Philadelphia

Columbia

Memphis

Nashville

Dallas

DeSoto

Houston

Lake Jackson

Wichita Falls

Midvale

Woodstock

Richmond

Seattle

Brown Deer

Middleton

Milwaukee

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

H. Lundbeck A/S

INDUSTRY

lead

Takeda

INDUSTRY

NCT00730691 - Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder | Biotech Hunter | Biotech Hunter